ABP 501 与阿达木单抗治疗中重度类风湿关节炎的疗效与安全性:随机双盲 III 期等效性研究
这项随机双盲 III 期等效性研究纳入 526 例甲氨蝶呤应答不足的中重度活动性类风湿关节炎患者,按 1:1 随机接受 ABP 501 或阿达木单抗 40 mg 每两周一次,治疗 26 周。第 24 周 ACR20 风险比(90%CI)为 1.039(0.954,1.133),落在预设等效区间 0.738–1.355 内,证实 ABP 501 与阿达木单抗在疗效、安全性和免疫原性方面相似。
要点
- 第 24 周 ACR20 风险比 90%CI 为 1.039(0.954,1.133),落在等效区间 0.738–1.355 内。
- ABP 501 组与阿达木单抗组 ACR20 分别为 74.6% 与 72.4%,DAS28-CRP、ACR50、ACR70 变化相似。
- 抗药结合抗体阳性率分别为 38.3% 与 38.2%,不良事件与实验室异常无临床有意义差异。
核心结论
- ABP 501 在中重度类风湿关节炎患者中的临床疗效、安全性和免疫原性与阿达木单抗相似。
研究设计与样本
- 随机、双盲、活性对照、26 周等效性 III 期研究,纳入甲氨蝶呤治疗后仍为中重度活动性 RA 的患者 526 例,按 1:1 随机接受 ABP 501 或阿达木单抗 40 mg 每两周一次。
主要发现
- 第 24 周 ACR20 应答率 ABP 501 组为 74.6%、阿达木单抗组为 72.4%。
- 第 24 周两组 ACR20 风险比(90%CI)为 1.039(0.954,1.133),确认等效性假设。
- DAS28-CRP、ACR50 和 ACR70 自基线变化相似,不良事件与实验室异常无临床有意义差异。
- 抗药结合抗体阳性率 ABP 501 组为 38.3%、阿达木单抗组为 38.2%。
关键数值与推荐
- 主要终点为第 24 周组间 ACR20 风险比,若其 90%CI 落在 0.738 至 1.355 之间则确认等效。
- 共 526 例患者随机(ABP 501 组 264 例,阿达木单抗组 262 例),494 例完成研究。
临床怎么用
- 该研究支持 ABP 501 作为阿达木单抗生物类似药用于中重度类风湿关节炎的临床等效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. METHODS: In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab. Secondary endpoints included Disease Activity Score 28-joint count-C reactive protein (DAS28-CRP). Safety was assessed via adverse events (AEs) and laboratory evaluations. Antidrug antibodies were assessed to determine immunogenicity. RESULTS: A total of 526 patients were randomised (n=264, ABP 501; n=262 adalimumab) and 494 completed the study. ACR20 response at week 24 was 74.6% (ABP 501) and 72.4% (adalimumab). At week 24, the RR of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133), confirming the primary hypothesis. Changes from baseline in DAS28-CRP, ACR50 and ACR70 were similar. There were no clinically meaningful differences in AEs and laboratory abnormalities. A total of 38.3% (ABP 501) and 38.2% (adalimumab) of patients tested positive for binding antidrug antibodies. CONCLUSIONS: Results from this study demonstrate that ABP 501 is similar to adalimumab in clinical efficacy, safety and immunogenicity in patients with moderate to severe RA. TRIAL REGISTRATION NUMBER: NCT01970475; Results.
引用
- Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017. PMID: 28584187. doi:10.1136/annrheumdis-2016-210459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。